First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
文献类型:期刊论文
作者 | Bai, X.19; Chen, Y.19; Chen, Y.1,2,3; Liang, X.4![]() ![]() |
刊名 | ANNALS OF ONCOLOGY
![]() |
出版日期 | 2024-07-01 |
卷号 | 35 |
ISSN号 | 0923-7534 |
资助项目 | Innovent Biologics (Suzhou) Co., Ltd. |
WOS研究方向 | Oncology |
语种 | 英语 |
WOS记录号 | WOS:001301473300002 |
出版者 | ELSEVIER |
资助机构 | Innovent Biologics (Suzhou) Co., Ltd. |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/135416] ![]() |
专题 | 中国科学院合肥物质科学研究院 |
作者单位 | 1.Fujian Canc Hosp, VIP Ward, Fuzhou, Peoples R China 2.Fujian Canc Hosp, Dept Clin Nutr, Fuzhou, Peoples R China 3.Fujian Canc Hosp, Canc Bioimmunotherapy Ctr, Fuzhou, Peoples R China 4.Hubei Canc Hosp, Abdominal Med, Wuhan, Peoples R China 5.Hunan Canc Hosp, Chest Radiotherapy Dept 1, Changsha, Peoples R China 6.Shandong First Med Univ, Affiliated Canc Hosp, Phase Clin Res Ctr 1, Shandong Canc Hosp,Shandong Canc Prevent & Treatm, Jinan, Peoples R China 7.Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China 8.Anhui Prov Hosp, Med Oncol, Hefei, Peoples R China 9.First Hosp Jilin Univ, Oncol, Changchun, Peoples R China 10.Peking Univ, Second Dept Thorac Tumors, Canc Hosp, Beijing, Peoples R China |
推荐引用方式 GB/T 7714 | Bai, X.,Chen, Y.,Chen, Y.,et al. First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study[J]. ANNALS OF ONCOLOGY,2024,35. |
APA | Bai, X..,Chen, Y..,Chen, Y..,Liang, X..,Wang, H..,...&Liang, T..(2024).First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study.ANNALS OF ONCOLOGY,35. |
MLA | Bai, X.,et al."First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study".ANNALS OF ONCOLOGY 35(2024). |
入库方式: OAI收割
来源:合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。